European Commission President Ursula von der Leyen has survived a no-confidence vote over text messages she sent to Pfizer CEO Albert Bourla during the Covid pandemic https://t.co/vJ9oJhuoS0 ...

对进口药品征收关税可能大幅推高美国药品的价格。对此许多制药公司已经表示反对，并警告称，征税可能会推高成本，阻碍在美国的投资，扰乱药品供应 链，使患者面临风险。 对进口药品征收关税可能大幅推高美国药品的价格。对此许多制药公司已经表示反对，并警告称，征税可能会推高成本，阻碍在美国的投资，扰乱药品供应 链，使患者面临风险。 辉瑞公司CEO艾伯乐（Albert Bourla）此前表示，关税威胁正在阻碍辉瑞进一步在美国进行研发和制造方面的投资。礼来公司CEO戴文睿（Dave Ricks）也 表示，他并不认为关税能解决围绕美国药品供应链的"国家安全"担忧。 美国总统特朗普在近日的一场内阁会议上表示，很快将宣布对美国进口药品征收"非常高"的关税。"比如200%。"特朗普称。 以默沙东的重磅抗癌药帕博利珠单抗（Keytruda）为例，该药物是目前全球处方药的"销量冠军"，大部分产自爱尔兰。默沙东此前已经表示，正在将足够的 库存转移到美国，以保障至少到年底前的供应。 一位医疗行业投资人对第一财经记者表示，很多美国制药巨头的生产线都建在美国以外的地区，例如爱尔兰每年境内生产的药品价值规模高峰时接近1000亿 欧元，辉瑞、礼来、艾 ...

Key Takeaways JNJ expects 2025 to be a catalyst year, with accelerating growth in the second half of the decade. PFE faces declining COVID revenues and upcoming patent expirations for several key drugs. JNJ forecasts 5-7% annual growth in Innovative Medicine from 2025 to 2030Johnson & Johnson (JNJ) and Pfizer (PFE) rank among the world’s largest pharmaceutical companies, each with broad and diversified healthcare portfolios. J&J operates primarily through its pharmaceuticals and medical devices segments. ...

Sally Susman, who has presided over Pfizer’s public communications for nearly two decades, will leave the company this year as part of a broader corporate restructuring https://t.co/KpxINBMMqE ...

Core Insights - The article emphasizes the importance of dividends in investment strategies, highlighting that even renowned investors like Warren Buffett recognize their value, despite Berkshire Hathaway not paying dividends [1] Company Summaries - **Pfizer**: Pfizer has a recent dividend yield of 7.1%, with total annual dividends increasing from $1.20 in 2016 to $1.70 recently. Despite poor stock performance averaging annual gains of 1.84% over the past decade, the company has a promising drug pipeline and a low forward P/E ratio of 8.3 compared to its five-year average of 10.2 [4] - **Caterpillar**: Caterpillar offers a dividend yield of 1.56%, above the S&P 500's yield of approximately 1.25%. The company has shown solid long-term performance with average annual gains of 17.6% over the past decade, and its total annual dividend has grown from $3.28 in 2018 to $5.64 recently [5] - **United Parcel Service (UPS)**: UPS has a dividend yield of 6.5%, with total payouts increasing from $3.64 in 2018 to $6.54 recently. The stock has had an average annual gain of 4.24% over the past decade, although growth has slowed recently due to economic uncertainties and competition from Amazon [6][7] - **Chevron**: Chevron's recent dividend yield stands at 4.78%, with total annual payouts rising from $4.76 in 2019 to $6.68 recently. The stock has averaged 14.2% annual growth over the past five years, supported by significant share buybacks and diversification in energy production and refining [8] ETF Considerations - The article suggests considering dividend-focused ETFs for investment, listing several options with their recent yields and average annual returns: - iShares Preferred & Income Securities ETF (PFF): 6.68% yield, 5-year average return of 3.22% - Schwab U.S. Dividend Equity ETF (SCHD): 3.97% yield, 5-year average return of 13.34% - Fidelity High Dividend ETF (FDVV): 3.02% yield, 5-year average return of 17.91% - Vanguard High Dividend Yield ETF (VYM): 2.86% yield, 5-year average return of 14.60% [9]

One formula to generate strong returns on equity markets involves investing small amounts of money in top stocks regularly over long periods. Buying fractional shares is one way to apply this strategy, but it's also possible to find attractive corporations at already-affordable prices.Here are two excellent examples in the healthcare industry: Pfizer (PFE 0.30%) and Exelixis (EXEL 3.72%). These drugmakers are worth investing in, and both are changing hands for under $50 apiece. Here is what investors need t ...

The parabolic ascent of artificial intelligence (AI) superstar Palantir Technologies may be short-lived.Since late 2022, no investment trend has been hotter on Wall Street than the evolution of artificial intelligence (AI). Allowing AI-empowered software and systems to make split-second decisions and grow more efficient at their tasks over time is a game-changing technology that offers utility in most industries around the globe.In Sizing the Prize, the analysts at PwC pegged AI's worldwide addressable mark ...

阿尔茨海默+减肥药，阿尔茨海默领域服务欧美药企，为小分子减肥药提供中间体，客户包括礼来、辉瑞 等巨头，在中美均设有研发生产中心，这家公司可为客户提供含氟药物中间体或原料药的定制服务。 前言 《电报解读》是一款主打时效性和专业性的即时资讯解读产品。侧重于挖掘重要事件的投资价值、分析 产业链公司以及解读重磅政策的要点。即时为用户提供快讯信息对市场影响的投资参考，将信息的价值 用专业的视角、朴素的语言、图文并茂的方式呈现给用户。 ...

Core Viewpoint - Pfizer Inc. has seen a decline in its dividend yield from 7.5% in late April to approximately 6.9% currently, indicating a shift in the investment landscape for the company [1]. Company Analysis - Pfizer Inc. is currently offering a dividend yield of around 6.9%, down from 7.5% earlier in the year, which may affect investor sentiment and decisions [1]. Investment Strategy - The investment philosophy emphasizes thorough research and a long-term perspective, focusing on value stocks while maintaining exposure to growth opportunities [1].

Key Takeaways PFE has traded above its 50-day SMA since the end of May, marking a short-term bullish trend. Pfizer's new products and Seagen deal are driving growth despite falling COVID sales and patent expirations. PFE trades below its 5-year average P/E, offering value amid high dividends and cost-cutting efforts.Pfizer (PFE) has reached a significant support level, making it an attractive option for investors from a technical standpoint. Since the end of May, the stock has been trading above its 50-da ...